Trial Profile
Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Prednisolone
- Indications Lupus nephritis
- Focus Proof of concept; Therapeutic Use
- Acronyms RITUXILUP
- 19 May 2017 Planned End Date changed from 1 Apr 2019 to 1 Mar 2018.
- 19 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2017.
- 04 Sep 2015 Accrual to date is 1% as reported by the United Kingdom Clinical Research Network record.